Sign In
Register
eISSN:2278-5299

International Journal of Latest Research in Science and Technology

DOI:10.29111/ijlrst   ISRA Impact Factor:3.35,  Peer-reviewed, Open-access Journal

A News Letter Sign UP!
INHIBITION of GSK-3β SUPPRESSES GLIOMA CELLS PROLIFERATION by DOWN-REGULATING MUTANT p53

Open Access

International Journal of Latest Research in Science and Technology Vol.8 Issue 3, pp 7-11,Year 2019

INHIBITION OF GSK-3β SUPPRESSES GLIOMA CELLS PROLIFERATION BY DOWN-REGULATING MUTANT P53

Chan Liu, Dongling Zhang, Yaling Tian, Chenli Lin

Correspondence should be addressed to :

Received : 06 May 2019; Accepted : 12 May 2019 ; Published : 30 June 2019

Share
Download 128
View 183
Article No. 10974
Abstract

Glycogen synthase kinase-3β (GSK-3β) has been identified as a therapeutic target for many diseases and is associated with tumor suppressor or pro-cancer mechanisms in many tumors. Mutant p53 plays a carcinogenic role in most tumors. Glioma is an intracranial tumor with high incidence, poor therapeutic effect and easy recurrence. The present research aims to investigate the regulation and effects of GSK-3β on mutant p53 and its biological role in glioma development. In addition, the effect of GSK-3β inhibitor 1-AKP interfering with GSK-3β on cell proliferation was studied in glioma cells. And the effects of lentivirus-mediated RNA interference of p53 on glioma cell proliferation. GSK-3β can positively regulate p53 and inhibition of GSK-3β could down-regulate the expression of mutant p53 thus inhibiting the proliferation of glioma cells. To sum up, GSK-3β inactivation regulates cell proliferation by inhibiting the expression of mutant p53.

Key Words   
Glioma, GSK-3β, 1-AKP, Mutant p53, Cell proliferation

Copyright
References
  1. Prados MD, Byron SA, Tran NL, et al. Toward precision medicine in glioblastoma: the promise and the challenges[J]. Neuro Oncol, 2015, 17(8): 1051-1063.
  2. Ji CX, Fan YH, Xu F, et al. MicroRNA-375 inhibits glioma cell proliferation and migration by downregulating RWDD3 in vitro[J]. Oncol Rep, 2018, 39(4): 1825-1834.
  3. Roger Stupp WPM, Martin J. van den Bent, , Michael Weller BF. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma[J]. The New England Journal of Medicine, 2005.
  4. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas - implications for classification and therapy[J]. Nat Rev Clin Oncol, 2017, 14(7): 434-452.
  5. Park SY, Choi YW, Park G. Nrf2-mediated neuroprotection against oxygen-glucose deprivation/reperfusion injury by emodin via AMPK-dependent inhibition of GSK-3beta[J]. J Pharm Pharmacol, 2018, 70(4): 525-535.
  6. Sahin I, Eturi A, De Souza A, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses[J]. Cancer Biol Ther, 2019: 1-10.
  7. Schubert F, Rapp J, Brauns-Schubert P, et al. Requirement of GSK-3 for PUMA induction upon loss of pro-survival PI3K signaling[J]. Cell Death Dis, 2018, 9(5): 470.
  8. McCubrey JA, Davis NM, Abrams SL, et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy[J]. Adv Biol Regul, 2014, 54: 176-196.
  9. Yang Yang YJ, Qinwei Sun, Haibo Dong, Ruqian Zhao. White light emitting diode induces autophagy in hippocampal neuron cells through GSK-3-mediated GR and RORα pathways[J]. Aging, 2019, 11(6): 1832—1849.
  10. Wang Z, Smith KS, Murphy M, et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy[J]. Nature, 2008, 455(7217): 1205-1209.
  11. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation[J]. Biochem Biophys Res Commun, 2005, 334(4): 1365-1373.
  12. Charvet C, Wissler M, Brauns-Schubert P, et al. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53[J]. Mol Cell, 2011, 42(5): 584-596.
  13. Zou Q, Hou Y, Shen F, et al. Polarized regulation of glycogen synthase kinase-3beta is important for glioma cell invasion[J]. PLoS One, 2013, 8(12): e81814.
  14. Wang J, Zou Y, Wu X, et al. DACH1 inhibits glioma invasion and tumor growth via the Wnt/catenin pathway[J]. Onco Targets Ther, 2018, 11: 5853-5863.
  15. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells[J]. Cell, 2012, 149(1): 36-47.
  16. Lv T, Wu X, Sun L, et al. p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis[J]. Cell Death Dis, 2017, 8(8): e2995.
  17. Zajkowicz A, Gdowicz-Klosok A, Krzesniak M, et al. The Alzheimer's disease-associated TREM2 gene is regulated by p53 tumor suppressor protein[J]. Neurosci Lett, 2018, 681: 62-67.
  18. Watcharasit P, Bijur GN, Song L, et al. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53[J]. J Biol Chem, 2003, 278(49): 48872-48879.
  19. Rana Dajani EF, S. Mark Roe, Neville Young,Valerie Good,Trevor C. Dale, and Laurence H. Pearl. Crystal Structure of Glycogen Synthase Kinase 3b: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition[J]. Cell, 2001, 105: 721–732.
  20. Lander R, Nasr T, Ochoa SD, et al. Interactions between Twist and other core epithelial-mesenchymal transition factors are controlled by GSK3-mediated phosphorylation[J]. Nat Commun, 2013, 4: 1542.
  21. Sun WL, Kang T, Wang YY, et al. Long noncoding RNA OIP5-AS1 targets Wnt-7b to affect glioma progression via modulation of miR-410[J]. Biosci Rep, 2019, 39(1).
  22. Zhang M, Zhang J, Chen X, et al. Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1[J]. Genes Dev, 2013, 27(20): 2246-2258.
  23. McCubrey JA, Rakus D, Gizak A, et al. Effects of mutations in Wnt/beta-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer[J]. Biochim Biophys Acta, 2016, 1863(12): 2942-2976.
  24. Feng ZC, Donnelly L, Li J, et al. Inhibition of Gsk3b activity improves b-cell function in c-KitWv/ þ male mice[J]. Lab Invest, 2012, 92(4): 543-555.
  25. Zhao D, Tahaney WM, Mazumdar A, et al. Molecularly targeted therapies for p53-mutant cancers[J]. Cellular and Molecular Life Sciences, 2017, 74(22): 4171-4187.
  26. Yue X, Zhao Y, Xu Y, et al. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy[J]. J Mol Biol, 2017, 429(11): 1595-1606.
  27. Hanel W, Moll UM. Links between mutant p53 and genomic instability[J]. J Cell Biochem, 2012, 113(2): 433-439.
To cite this article

Chan Liu, Dongling Zhang, Yaling Tian, Chenli Lin , " Inhibition Of Gsk-3β Suppresses Glioma Cells Proliferation By Down-regulating Mutant P53 ", International Journal of Latest Research in Science and Technology . Vol. 8, Issue 3, pp 7-11 , 2019

Responsive image

MNK Publication was founded in 2012 to upholder revolutionary ideas that would advance the research and practice of business and management. Today, we comply with to advance fresh thinking in latest scientific fields where we think we can make a real difference and growth now also including medical and social care, education,management and engineering.

Responsive image

We offers several opportunities for partnership and tie-up with individual, corporate and organizational level. We are working on the open access platform. Editors, authors, readers, librarians and conference organizer can work together. We are giving open opportunities to all. Our team is always willing to work and collaborate to promote open access publication.

Responsive image

Our Journals provide one of the strongest International open access platform for research communities. Our conference proceeding services provide conference organizers a privileged platform for publishing extended conference papers as journal publications. It is deliberated to disseminate scientific research and to establish long term International collaborations and partnerships with academic communities and conference organizers.